TAVI FORUM 14, was held on Friday, April 17, 2026 in Munich, Germany
Materials
Introductory Remarks
Welcome and Introductions
Shilpa Mitra, Forum for Collaborative Research
Veronica Miller, Forum for Collaborative Research
Per Ljungman, Karolinska Institutet
Camille Kotton, Massachusetts General Hospital
Session I: Adenovirus Updates
ADENOCLEAR Study: Preliminary Results
Jérôme Le Goff, Université Paris Cité
Brincidofovir Phase 3 Study Against AdV: ENOVIA Launched
Nkechi Azie, Symbio Pharmaceuticals Ltd
Discussion
All Meeting Participants
Session II: CMV Updates
Cytogam in the Modern Era: Investigator-Initiated Study Updates
Winston Ally, Kamada Ltd.
CMV CMI in Hematopoietic Cell Transplant
Guy Handley, UT MD Anderson Cancer Center
CMV CMI in Solid Organ Transplant
Cesar Berto, University of Alabama at Birmingham
Discussion
All Meeting Participants
Session III: BK Polyomavirus Updates
AIC468: A first-in-class antiviral antisense oligonucleotide in clinical development for the treatment of BKV in kidney transplant recipients
Peter Lischka, AiCuris Anti-Infective Cures AG
VP1-Targeting Small Molecules for BK Polyomavirus: Toward Direct-Acting Antivirals with Cross-Polyomavirus Activity
Ali Munawar, Orthogon Therapeutics LLC
Potravitug
Juergen Beck, Memo Therapeutics AG
TAVI Forum BK Project Update: Leuven/Roche
Maarten Naesens, Leuven University Hospital
Discussion
All Meeting Participants
Session IV: Herpes Viruses Updates
Pritelivir, Novel Helicase Primase Inhibitor, Phase 3 Trial Results
Genovefa Papanicolaou, Memorial Sloan Kettering Cancer Center
Pritelivir, Novel Helicase Primase Inhibitor, for the treatment of refractory HSV infection: NDA Progress & Pathway to Launch
Cynthia Wat, AiCuris Anti-Infective Cures AG
Gilead’s HSV Program
Yoshihiko Murata, Gilead Sciences Inc.
Kaposi Sarcoma–Associated Herpesvirus (HHV-8) Infection in Solid Organ Transplant Recipients: State of the Art and Open Challenges
Alessandra Mularoni, ISMETT
TAVI Forum HHV-6 Project Update
Per Ljungman, Karolinska Institutet
Discussion
All Meeting Participants
Session V: New Topics in Transplant and Immunocompromised Populations
Tabelecleucel, an allogeneic cell therapy for EBV+ PTLD: Clinical Program Update
Ruchit Parikh, Pierre-Fabre Pharmaceuticals
VMS063: a novel, highly potent, half-life extended, pan-measles variant antibody
Robert Allen, Invivyd Inc.
MSD’s Respiratory Virus Programs
Michael Wong, Merck & Co. Inc.
The Urgent Need for Therapeutic Innovation in Kidney Transplantation
Kevin Fowler, The Voice of the Patient
Discussion
All Meeting Participants
Concluding Remarks
Next Steps
Veronica Miller, Forum for Collaborative Research
Per Ljungman, Karolinska Institutet
Camille Kotton, Massachusetts General Hospital